Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention
AuthorMetz, DK; Holford, N; Kausman, JY; Walker, A; Cranswick, N; Staatz, CE; Barraclough, KA; Ierino, F
PublisherLIPPINCOTT WILLIAMS & WILKINS
University of Melbourne Author/sCranswick, Noel; Ierino, Francesco; Kausman, Joshua; Walker, Amanda; Barraclough, Katherine; Metz, David
AffiliationPharmacology and Therapeutics
Medicine and Radiology
Document TypeJournal Article
CitationsMetz, D. K., Holford, N., Kausman, J. Y., Walker, A., Cranswick, N., Staatz, C. E., Barraclough, K. A. & Ierino, F. (2019). Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. TRANSPLANTATION, 103 (10), pp.2012-2030. https://doi.org/10.1097/TP.0000000000002762.
Access StatusOpen Access
The immunosuppressive agent mycophenolate is used extensively in kidney transplantation, yet dosing strategy applied varies markedly from fixed dosing ("one-dose-fits-all"), to mycophenolic acid (MPA) trough concentration monitoring, to dose optimization to an MPA exposure target (as area under the concentration-time curve [MPA AUC0-12]). This relates in part to inconsistent results in prospective trials of concentration-controlled dosing (CCD). In this review, the totality of evidence supporting mycophenolate CCD is examined: pharmacological characteristics, observational data linking exposure to efficacy and toxicities, and randomized controlled trials of CCD, with attention to dose optimization method and exposure achieved. Fixed dosing of mycophenolate consistently leads to underexposure associated with rejection, as well as overexposure associated with toxicities. When CCD is driven by pharmacokinetic calculation to a target concentration (target concentration intervention), MPA exposure is successfully controlled and clinical benefits are seen. There remains a need for consensus on practical aspects of mycophenolate target concentration intervention in contemporary tacrolimus-containing regimens and future research to define maintenance phase exposure targets. However, given ongoing consequences of both overimmunosuppression and underimmunosuppression in kidney transplantation, impacting short- and long-term outcomes, these should be a priority. The imprecise "one-dose-fits-all" approach should be replaced by the clinically proven MPA target concentration strategy.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References